Phase II trial: concurrent radio-chemotherapy with weekly docetaxel for advanced squamous cell carcinoma of head and neck
✍ Scribed by A. Biete Solà; J. Marruecos Querol; F. A. Calvo Manuel; E. Verger Fransoy; À. Rovirosa Casino; J. J. Grau de Castro; M. de las Heras González; A. Ramos Aguerri; A. Palacios Eito; C. Veiras Candal; Mª. V. Solano López
- Book ID
- 107596210
- Publisher
- Springer Milan
- Year
- 2007
- Tongue
- Spanish
- Weight
- 469 KB
- Volume
- 9
- Category
- Article
- ISSN
- 1699-048X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ## BACKGROUND The authors conducted a Phase I/II study in patients with a poor prognosis who had locally advanced squamous cell carcinoma of the head and neck (SCCHN) and who were treated initially with induction chemotherapy. Patients were treated with weekly docetaxel and concurrent
## Abstract Fifty‐one patients (32 previously untreated, 19 previously treated) with advanced squamous cell carcinoma of the head and neck received a single course of combination chemotherapy consisting of high dose __cis__‐platinum (DDP), bleomycin (Bleo), ± high dose methotrexate (MTX). Thirty‐th
## Abstract ## BACKGROUND The current Phase I/II study assessed induction docetaxel/carboplatin given weekly for 4 weeks, followed by weekly docetaxel/carboplatin and concomitant boost radiotherapy (CB‐XRT) for locally advanced head and neck squamous cell carcinoma. ## METHODS Twenty patients wi